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A phase II NCCTG “Window of Opportunity Front-line” study 
of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single 
agent in patients with advanced NSCLC 
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Background: Over-expression of Akt and loss of PTEN are frequent 
events in non-small cell lung cancer (NSCLC). The mammalian target 
of rapamycin (mTOR) is a protein downstream to Akt in the phosphati-
dylinositol 3-kinase (PI3K)/Akt signaling pathway. CCI-779 (temsi-
rolimus), an ester of sirolimus, is an inhibitor of mTOR with growth 
inhibitory activity in a variety of tumor cells. In an effort to evaluate 
the single agent activity of CCI-779 in previously untreated NSCLC, 
the NCCTG undertook a front-line “window of opportunity” study.
Methods: N0323 was a two-stage single arm phase II trial which 
evaluated the response and toxicity rates of CCI-779 administered as 
a front line single agent treatment for stage IIIB (pleural effusion) or 
IV NSCLC. Fresh tumor biopsies were obtain to evaluate predictive 
markers of CCI-779 activity and target inhibition such as phospho AKT 
expression and loss of PTEN. Patients received 25 mg of CCI-779 
administered intravenously as a 30 minute infusion on days 1, 8, 15, 
and 22 in4 week cycles. Based on a two-stage Fleming design with an 
exact signiﬁcance level of 0.05 and 94% power to detect an effec-
tive treatment if the true CRR was at least 20%, this treatment would 
be promising if at least 4 of the ﬁrst 25 evaluable patients in Stage I 
or at least 6 of the 50 evaluable patients at the end of Stage II have a 
conﬁrmed response. 
Results: A total of 55 patients were accrued from February 2004 to 
November 2006 and results from the ﬁrst 50 evaluable patients are 
reported here. Patient characteristics included a median age of 64 years 
(range: 44-85); 38% of patients were female; 84% had stage IV disease, 
and 89% were ECOG PS of 0 or 1. Median number of cycles adminis-
trated was 2 (range 1-18). One patient is still receiving active treatment 
(28 weeks). The most common grade 3/4 events were dyspnea (12%), 
fatigue (10%), hyperglycemia (8%), hypoxia (8%), nausea (8%), and 
rash/desquamation (6%). The clinical beneﬁt rate was 38% with 4 (8%: 
95% CI: 0.03-0.22) conﬁrmed partial responses and 15 (30%: 95% 
CI: 0.14-0.48) stable disease for a minimum of 56 days. The 24-week 
progression-free survival (PFS) rate was 22% (11/50; 95% CI: 0.12-
0.36). The median PFS and overall survival were respectively 2.3 and 
6.6 months. Sixteen (32%) patients received subsequent treatment after 
progressing on CCI-779. 
Conclusions: CCI-779 (Temsirolimus) given as a single agent front 
line therapy in patients with NSCLC produced a clinical beneﬁt rate of 
38% (8% PR, 30% SD). While the study did not meet the predeﬁned 
success criteria, single agent CCI-779 has activity similar to other 
signal transduction inhibitors and had good tolerability. Proper patient 
selection may enhance efﬁcacy. The potential predictive markers of 
efﬁcacy such as p70S-kinase phosphorylation and PTEN expression are 
being evaluated and these results will be presented.
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Association between lung cancer incidence and family history of 
lung cancer
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Study Objectives: To clarify the possibility of a hereditary predisposi-
tion to lung cancer, we investigated the association between a family 
history of lung cancer and subsequent risk of lung cancer in a large-
scale, population-based cohort study.
Design: We investigated 102,255 middle-aged and older Japanese sub-
jects (48,834 men and 53,421 women) with 13-year follow-up. A total 
of 791 cases of lung cancer were newly diagnosed during the follow-up 
period. 
Results: A family history of lung cancer in a ﬁrst-degree relative was 
associated with a signiﬁcantly increased risk of lung cancer (hazard 
ratio [HR], 1.95; 95% conﬁdence interval [CI], 1.31 to 2.88). The 
association was stronger in women than in men (HR, 2.65; 95% CI, 
1.40 to 5.01 and HR, 1.69; 95% CI, 1.03 to 2.78, respectively), and in 
never-smokers than in current smokers (HR, 2.48; 95% CI, 1.27 to 4.84 
and HR, 1.73; 95% CI, 0.99 to 3.00, respectively). In addition, family 
history was more strongly associated with the risk of squamous cell 
carcinoma than with other histologic types (HR, 2.79; 95% CI, 1.37 to 
5.68), while no clear increase in risk was observed in adenocarcinoma 
and small cell carcinoma. A family history of overall cancer was not 
associated with an increased risk of lung cancer.
Conclusions: These results suggest that those with a family history of 
lung cancer are more likely to acquire lung cancer themselves.
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The significant influence of smoking status and gender on the 
clinical outcome in the patients with non-small cell lung cancer: a 
large-scale population based cohort study
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Background: To determine retrospectively whether smoking status 
and gender affect the treatment outcome and survival for the Japanese 
patients with non-small cell lung cancer. 
Methods: Using the database from the lung cancer registry of the 
National Hospital Study Group for Lung Cancer between 1987 and 
